Follow us on:

Linkedin Facebook

Cue Biopharma, Inc. – Consensus Indicates Potential 249.4% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Cue Biopharma, Inc. with ticker code (CUE) have now 5 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 28 and 7 with the average target price sitting at 13.8. Given that the stocks previous close was at 3.95 this indicates there is a potential upside of 249.4%. The 50 day MA is 3.03 and the 200 day MA is 3.6. The company has a market capitalisation of $126m. You can visit the company’s website by visiting: https://www.cuebiopharma.com

The potential market cap would be $441m based on the market concensus.

0

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Latest Company News

    Broker Ratings

    Cue Biopharma, Inc. – Consensus ‘Strong_Buy’ rating and 187.4% Upside Potential

    Broker Ratings

    Cue Biopharma, Inc. – Consensus ‘Strong_Buy’ rating and 195.9% Upside Potential

    Broker Ratings

    Cue Biopharma, Inc. – Consensus ‘Strong_Buy’ rating and 133.3% Upside Potential

    Broker Ratings

    Cue Biopharma, Inc. – Consensus Indicates Potential 249.8% Upside

    Broker Ratings

    Cue Biopharma, Inc. – Consensus Indicates Potential 201.5% Upside

    Broker Ratings

    Cue Biopharma, Inc. – Consensus Indicates Potential 186.3% Upside

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.